Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – XTI Aerospace, Inc. (NASDAQ: XTIA) Highlights Revenue Visibility and Operating Leverage at Shareholder Town Hall
XTI Aerospace (NASDAQ: XTIA), an aerospace technology company focused on scaling its Drone Nerds, LLC subsidiary,…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Will Highlight the Company’s AI Capabilities for Military Engineers at Upcoming 2026 Defence Leaders Combat Engineer & Logistics Conference
Safe Pro Group will present at the 2026 Defence Leaders Combat Engineer & Logistics Conference…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This…